SLC5A2 and hydrops fetalis: The three main SGLT2 inhibitors (empagliflozin, canagliflozin and dapagliflozin) lowered the risk of hospitalization for HF by ∼25 to 35%, with the benefits almost immediately apparent on the initiation of treatment and persisted throughout the follow-up period of 2–5 years.